Stockscreener 앱 받기
0.4002
29.14%
0.0903
시간 외 거래:
.38
-0.0202
-5.05%
Outlook Therapeutics Inc 주식(OTLK)의 최신 뉴스
OTLK - Finviz
OTLK stock surges over 50% pre-market, breaches key technical milestone – what’s behind this massive rally? - MSN
Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA - Benzinga
OTLK Stock Surges Over 50% Pre-Market, Breaches Key Technical Milestone – What’s Behind This Massive Rally? - Yahoo Finance
Outlook Therapeutics Wins FDA Appeal, Plans June 2026 Resubmission for ONS-5010/LYTENAVA™ (Bevacizumab) for Wet AMD Approval 1 - Minichart
Outlook Therapeutics stock surges after winning FDA appeal - Investing.com
Outlook Therapeutics (OTLK) Gains FDA Appeal Approval for Lytenava - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Outlook Therapeutics says FDA finds substantial evidence of effectiveness for Lytenava in nAMD - marketscreener.com
Outlook Therapeutics wins FDA appeal, to resubmit LYTENAVA BLA in June 2026 - TradingView
[8-K] Outlook Therapeutics, Inc. Reports Material Event - Stock Titan
Outlook Therapeutics Wins Appeal Following Formal Dispute - GlobeNewswire
OTLK SEC FilingsOutlook Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Outlook Therapeutics (OTLK) seeks warrant issuances, 600M authorized shares, reverse split - Stock Titan
OTLK Technical Analysis | Trend, Signals & Chart Patterns | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
This Applied Materials analyst is no longer bullish; here are top 5 downgrades for Monday - MSN
BTIG downgrades Outlook Therapeutics (OTLK) - MSN
This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Sahm
Outlook Therapeutics Reports Second Quarter 2026 Financial Results - VisionMonday.com
OTLK Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
Outlook Therapeutics Reports Q2 2026 Financial Results, Updates on FDA Review and European Expansion of LYTENAVA (bevacizumab gamma) - Minichart
BTIG downgrades Outlook Therapeutics stock rating to neutral By Investing.com - Investing.com Australia
BTIG downgrades Outlook Therapeutics stock rating to neutral - Investing.com UK
BTIG Downgrades Outlook Therapeutics to Neutral From Buy - marketscreener.com
Outlook Therapeutics reports Q2 FY2026 net loss $4.5M, adjusted net loss $14.1M; FDA decision expected May 2026 - TradingView
Outlook Therapeutics Q2 Net Loss Narrows; Expects FDA Decision For LYTENAVA In May 2026 - RTTNews
Outlook Therapeutics (OTLK) Reports Q2 Revenue Below Expectations - GuruFocus
Outlook Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Outlook Therapeutics, Inc. 3Q 2026: Revenue $127K, EPS $(0.05) — 10-Q Summary - TradingView
OTLK: Net loss of $27.5M, negative revenue, and urgent funding needs amid ongoing U.S. regulatory delays - TradingView
Outlook Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
[10-Q] Outlook Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 - marketscreener.com
Outlook Therapeutics Q2 adjusted EPS misses analyst expectations - TradingView
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update - The Manila Times
Outlook Therapeutics stock (US69012T1051): new $100 million ATM highlights financing focus - AD HOC NEWS
Outlook Therapeutics IncEnters ATM offering agreement with H.C. Wainwright for up to $100 millionSEC filing - marketscreener.com
Outlook Therapeutics Launches New $100M ATM Offering - TipRanks
Outlook Therapeutics (OTLK) registers $100M ATM offering with H.C. Wainwright - Stock Titan
Outlook Therapeuticsenters sales agreement with H.C. Wainwright to offer and sell common stock up to $100 millionSEC filing - marketscreener.com
Outlook Therapeutics (NASDAQ: OTLK) adds $100M ATM, reports $7.7M cash - Stock Titan
Outlook Therapeutics | 8-K: Current report - Moomoo
Certain Warrants of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2026. - marketscreener.com
104,614,219 Common Stock of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-MAY-2026. - marketscreener.com
OTLK Stock Price, Quote & Chart | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
UBS Initiates Coverage of Amneal Pharmaceuticals (AMRX) With a Bullish Outlook - Yahoo Finance
Outlook Therapeutics Reports Closing of $5.0 Million Registered Direct Offering - VisionMonday.com
Outlook Therapeutics launches public offering; shares down - MSN
OTLK Price Today: Outlook Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Certain Warrants of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2026. - marketscreener.com
0.98%
0.12%
자본화:
|
볼륨(24시간):